Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
March 15 2023 - 7:00AM
Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("AI") and machine learning (“ML”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that the Company will present at
the American Association for Cancer Research (AACR) Annual Meeting.
Details on the AACR presentation are provided below:
- AACR Annual Meeting in Orlando, FL from April 14th-19th,
2023
- Poster Title: LP-184, an acylfulvene class small
molecule therapeutic, is synthetically lethal in DNA damage repair
deficient cancers
- Presentation Date and Time: Wednesday, April 19, 2023
from 9:00 a.m. – 12:30 p.m. ET
- Abstract Link:
https://www.abstractsonline.com/pp8/#!/10828/presentation/6762
- Registration:
https://www.aacr.org/meeting/aacr-annual-meeting-2023/registration/
The AACR presentation will focus on Lantern’s drug candidate
LP-184 and its unique anti-cancer mechanism of action known as
synthetic lethality. In oncology drug development, synthetic
lethality has become a highly desired capability for small
molecules as it promotes the selective anti-tumor toxicity of
cancer cells, while reducing potential side effects to normal
cells. This mechanism of action can exploit vulnerabilities in
cancer cells, known as DNA damage repair deficiencies, which are
common in 25-30% of solid tumors. Using synthetic lethality,
Lantern’s drug candidate LP-184 has demonstrated nanomolar potency
across a comprehensive number of in vitro and in vivo preclinical
models in solid tumors as well as in adult and pediatric central
nervous system cancers. Based on its synthetic lethality mechanism
of action and strong preclinical results, Lantern is targeting
advancing LP-184 to a first-in-human Phase 1 clinical trial in
mid-2023.
Lantern will also be hosting a key opinion leader webinar on
synthetic lethality on Tuesday, March 21, 2023 at 12:00 p.m. ET,
featuring a leading expert in synthetic lethality, Zoltan Szallasi,
M.D. Register for the webinar here.
About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® AI and machine learning platform
to discover biomarker signatures that identify patients most likely
to respond to its pipeline of genomically-targeted therapeutics. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma Lantern’s Monthly Newsletter – SPARK: Sign-up
here
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® AI platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230315005265/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024